BMS' Revlimid + Rituximab Receives EC's Approval to Treat Adults Previously Treated Follicular Lymphoma (Grade 1-3a)
Shots:
- The approval is based on P-III AUGUMENT study involves assessing of Revlimid + Rituximab (R2) vs rituximab +PBO in patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL)
- The study resulted improvement in 1EP mPFS (39.4 mos. vs 13.8 mos.) with median follow up 29.2 months. Additionally- the safety and efficacy of Revlimid + Rituximab in patients with relapsed or refractory FL including rituximabrefractory FL patients was supported by MAGNIFY study
- Revlimid (lenalidomide) + rituximab is the first chemotherapy-free combination regimen for patients with FL who have relapsed or did not respond to previous treatment and approved in the US- Canada- Switzerland- Australia- New Zealand and several Latin American countries
Click here to read full press release/ article
Ref: BMS | Image: BMS
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com